Výsledky vyhledávání

Mgta-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics and Pharmacodynamics Initial Findings from a Phase 1/2 Study

Autor: Peter Westervelt, Partow Kebriaei, Mark Juckett, Andrew S. Artz, Onyee Chan, Philip L. McCarthy, Sherif S Farag, Anurag K. Singh, Eytan Stein, Jeffrey Humphrey, William Baeder, Ji Hyun Lee, Alison Occhiuti, Jeanie Tang, David Santos, Kirk Bertelsen, Balaji Mahender, Nicole Henry, Shawn Rose

Publikováno v: Blood. 140:2117-2119

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1155997b95167e22b5f2493c0c928311
https://doi.org/10.1182/blood-2022-162406

Zobrazit plný text záznamu

Mgta-117, an Anti-CD117-Amanitin Antibody-Drug Conjugate, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics, and Pharmacodynamics Initial Findings from a Phase 1/2 Study

Publikováno v: Transplantation and Cellular Therapy. 29:S109-S110

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::510cf7f0b3469505b8e6c11756fcdea3
https://doi.org/10.1016/s2666-6367(23)00205-1

Zobrazit plný text záznamu

A phase Ib/II open-label study of tazemetostat (TAZ) plus enzalutamide (E) or abiraterone/prednisone (A/P) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Autor: Lawrence Karsh, Deyaa Adib, Daniel Saltzstein, Arash Rezazadeh, Thomas Bradley, Anthony Hamlett, Ashley E. Ross, Evren Kocabas Argon, Wassim Abida, Jeanie Tang

Publikováno v: Journal of Clinical Oncology. 38:TPS255-TPS255

TPS255 Background: The histone methyltransferase EZH2 is overexpressed in many cancers. In prostate cancer (PC), EZH2 inhibition may reverse acquired resistance to androgen inhibitors (AIs). Pts may initially respond to AIs, but pts who progress have

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::910335a32187dbdd9aa3e3d88fcf6718
https://doi.org/10.1200/jco.2020.38.6_suppl.tps255

Zobrazit plný text záznamu

A phase I study of the EZH2 inhibitor tazemetostat in pediatric subjects with relapsed or refractory INI1-negative tumors or synovial sarcoma

Autor: Stephen J. Blakemore, Susan N. Chi, Maria Roche, Susan Doleman, Alicia Clawson, Lindsey M. Hoffman, Scott R. Daigle, Jeanie Tang, Margaret E. Macy, Geoffrey McCowage, Peter T.C. Ho

Publikováno v: Journal of Clinical Oncology. 34:TPS10587-TPS10587

TPS10587Background: Tazemetostat is a potent and selective inhibitor of the histone methyltransferase enhancer of zeste-homolog 2 (EZH2), the catalytic subunit of the polycomb repressive complex 2 (PRC2). EZH2 is responsible for trimethylation of lys

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fc7dd419989e4ad9946e38b3e5bd1878
https://doi.org/10.1200/jco.2016.34.15_suppl.tps10587

Zobrazit plný text záznamu

A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adult subjects with INI1-negative tumors or relapsed/refractory synovial sarcoma

Autor: Susan Doleman, Alicia Clawson, Scott R. Daigle, Nizar M. Tannir, Stephen J. Blakemore, Mrinal M. Gounder, Joseph G. Pressey, Mark Agulnik, George D. Demetri, Gregory M. Cote, Jeanie Tang, Maria Roche, Peter T.C. Ho

Publikováno v: Journal of Clinical Oncology. 34:TPS11071-TPS11071

TPS11071Background: Tazemetostat is a potent and selective inhibitor of the histone methyltransferase enhancer of zeste-homolog 2 (EZH2), the catalytic subunit of the polycomb repressive complex 2 ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::68933d739b84010275f973bc0d43fa80
https://doi.org/10.1200/jco.2016.34.15_suppl.tps11071

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání